Literature DB >> 9091515

Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy.

M Satoh1, M Nakamura, G Tamura, S Makita, I Segawa, A Tashiro, R Satodate, K Hiramori.   

Abstract

OBJECTIVES: We examined the mRNA expression and protein localization of inducible nitric oxide synthase (iNOS) and tumor necrosis factor-alpha (TNF-alpha) in myocardial tissue obtained from patients with dilated cardiomyopathy (DCM).
BACKGROUND: The etiology of DCM is unknown, but viral infection or autoimmune abnormalities that induce cytokine expression have been proposed as pathogenetic factors. Nitric oxide (NO), synthesized by nitric oxide synthase (NOS), has negative inotropic and cytotoxic effects on cardiomyocytes. Cytokines such as TNF-alpha are potent stimulators of iNOS expression. Expression of iNOS leads to excessive production of NO in the myocardium and may modulate cardiac contractility and ventricular morphology.
METHODS: We examined the mRNA expression and protein localization of iNOS and TNF-alpha in myocardial tissue obtained from 24 patients with DCM, 20 patients with hypertrophic cardiomyopathy (HCM) and 15 control subjects, using the reverse transcriptase-polymerase chain reaction method and immunohistochemical studies. We then compared the differences in clinical characteristics between DCM patient subgroups with and without myocardial iNOS expression.
RESULTS: Messenger RNA expression of iNOS and TNF-alpha was observed, respectively, in 13 (54%) and 18 (75%) patients with DCM. Gene expression of TNF-alpha was consistently detected in endomyocardial tissue from patients with DCM and INOS expression. Inducible NOS protein was evident only in cardiomyocytes, whereas TNF-alpha was apparent in both cardiomyocytes and endomyocardial endothelium. Neither mRNA expression nor protein localization of iNOS or TNF-alpha was observed in cardiac tissue obtained from patients with HCM or control subjects. Patients with DCM and iNOS mRNA showed a lower left ventricular ejection fraction (p < 0.01) and a higher left ventricular volume (p < 0.05) than the negative DCM group.
CONCLUSIONS: Inducible NOS was consistently coexpressed with TNF-alpha in myocardial tissue obtained from a subgroup of patients with DCM and advanced left ventricular dysfunction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9091515     DOI: 10.1016/s0735-1097(96)00567-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  28 in total

Review 1.  Statins and the role of nitric oxide in chronic heart failure.

Authors:  Stephan von Haehling; Stefan D Anker; Eberhard Bassenge
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

2.  Inflammatory mediators in chronic heart failure: an overview.

Authors:  Stefan D Anker; Stephan von Haehling
Journal:  Heart       Date:  2004-04       Impact factor: 5.994

Review 3.  Inducible nitric oxide synthase in human diseases.

Authors:  K D Kröncke; K Fehsel; V Kolb-Bachofen
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

Review 4.  Cardiac dysfunction in sepsis: new theories and clinical implications.

Authors:  R M Grocott-Mason; A M Shah
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

Review 5.  Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications.

Authors:  A P Bolger; S D Anker
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

6.  Myocardial Fas and cytokine expression in end-stage heart failure: impact of LVAD support.

Authors:  Maninder S Bedi; Rene J Alvarez; Toru Kubota; Richard Sheppard; Robert L Kormos; Michael P Siegenthaler; Arthur M Feldman; Charles F McTiernan; Dennis M McNamara
Journal:  Clin Transl Sci       Date:  2008-12       Impact factor: 4.689

Review 7.  The role of nitric oxide in the failing heart.

Authors:  W J Paulus
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

8.  Effects of L-arginine on lower limb vasodilator reserve and exercise capacity in patients with chronic heart failure.

Authors:  Y Kanaya; M Nakamura; N Kobayashi; K Hiramori
Journal:  Heart       Date:  1999-05       Impact factor: 5.994

9.  Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences.

Authors:  Qianhong Li; Yiru Guo; Wei Tan; Adam B Stein; Buddhadeb Dawn; Wen-Jian Wu; Xiaoping Zhu; Xiaoqin Lu; Xiaoming Xu; Tariq Siddiqui; Sumit Tiwari; Roberto Bolli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-09-19       Impact factor: 4.733

Review 10.  Immune modulation: role of the inflammatory cytokine cascade in the failing human heart.

Authors:  Mamoru Satoh; Yoshitaka Minami; Yuji Takahashi; Motoyuki Nakamura
Journal:  Curr Heart Fail Rep       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.